Displaying drugs 6676 - 6700 of 8282 in total
Favezelimab
Favezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)).
Investigational
Matched Description: … Favezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and …
KITE-585
KITE-585 is an autologous, fully-human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy. It is being investigated in the treatment of multiple myeloma.
Investigational
Matched Description: … It is being investigated in the treatment of multiple myeloma. …
BN‐Brachyury vaccine
BN‐Brachyury vaccine is a novel prime‐boost therapeutic cancer immunotherapy. It is composed of the MVA-BN-brachyury-TRICOM vaccine and the fowlpox virus(FPV)‐Brachyury booster vaccine.
Investigational
Matched Description: … It is composed of the [MVA-BN-brachyury-TRICOM vaccine] and the fowlpox virus(FPV)‐Brachyury booster …
Eftansomatropin alfa
Eftansomatropin alfa (GX-H9) comprises a recombinant human growth hormone fused to hyFc, a synthetic hybrid Fc fragment. It is under investigation for the treatment of growth hormone deficiency.
Investigational
Matched Description: … [L48275] It is under investigation for the treatment of growth hormone deficiency. …
HMI-203
HMI-203 is an investigational gene therapy developed by Homology Medicines, Inc. It consists of a recombinant adeno-associated virus (AAV) serotype HSC15 (rAAVHSC15) encoding human iduronate-2-sulfatase (hIDS).
Investigational
Matched Description: … It consists of a recombinant adeno-associated virus (AAV) serotype HSC15 (rAAVHSC15) encoding human iduronate …
Irsenontrine
Irsenontrine is under investigation in clinical trial NCT03467152 (Study to Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies).
Investigational
Matched Description: … investigation in clinical trial NCT03467152 (Study to Evaluate the Efficacy, Safety and Tolerability of …
Estrane-3,17-dione
Estrane-3,17-dione is a potent inhibitor of isomerase.
Experimental
Matched Description: … Estrane-3,17-dione is a potent inhibitor of isomerase. …
MK-886
MK-886 is an experimental inhibitor of leukotriene synthesis.
Experimental
Matched Description: … MK-886 is an experimental inhibitor of leukotriene synthesis. …
Tabituximab barzuxetan yttrium Y-90
A version of tabituximab barzuxetan radiolabeled with yttrium-90.
Investigational
Matched Description: … A version of [tabituximab barzuxetan] radiolabeled with yttrium-90. …
Human interferon omega-1
Human interferon omega 1 (IFN-omega 1 = IFN-alpha II1) is a recently discovered protein structurally related to IFN-alpha and -beta. It occurs naturally in the human body and is currently being manufactured by Intarcia through genetic engineering. There are multiple routes for administration of omega interferon: injection, an implantable subcutaneous...
Investigational
Matched Description: … The biological activities of IFN-omega 1 and its physiological role are not known to date. ... There are multiple routes for administration of omega interferon: injection, an implantable subcutaneous …
Spaglumic acid
Spaglumic acid is the β-aspartyl isoform of N-Acetyl-l-aspartylglutamate (isospaglumic Acid is N-(N-Acetyl-l-α-aspartyl)-l-glutamic acid). In eye drops, spaglumic acid is either a magnesium or sodium salt of N-Acetyl-l-aspartylglutamate. Spaglumic acid is a mast cell stabilizer. Thus it is used in allergic conditions such as allergic conjunctivitis. Specifically spaglumic acid is approved...
Experimental
Matched Description: … In eye drops, spaglumic acid is either a magnesium or sodium salt of N-Acetyl-l-aspartylglutamate. ... Spaglumic acid is the β-aspartyl isoform of N-Acetyl-l-aspartylglutamate (isospaglumic Acid is N-(N-Acetyl-l-α-aspartyl …
4-Hydroxytestosterone
4-Hydroxytestosterone is testosterone substituted with a hydroxy group on the fourth carbon atom. It is an anabolic steroid with no therapeutic indications, which is prohibited from use in sports by the World Anti-Doping Agency.
Formestane (Lentaron) acts as a prohormone of 4-Hydroxytestosterone, as 4-Hydroxytestosterone is one of the many byproducts...
Experimental
Illicit
Matched Description: … of the many byproducts of formestane metabolism. ... Formestane (Lentaron) acts as a prohormone of 4-Hydroxytestosterone, as 4-Hydroxytestosterone is one …
Methylmalonic Acid
A malonic acid derivative which is a vital intermediate in the metabolism of fat and protein. Abnormalities in methylmalonic acid metabolism lead to methylmalonic aciduria. This metabolic disease is attributed to a block in the enzymatic conversion of methylmalonyl CoA to succinyl CoA. [PubChem]
Experimental
Matched Description: … A malonic acid derivative which is a vital intermediate in the metabolism of fat and protein. ... This metabolic disease is attributed to a block in the enzymatic conversion of methylmalonyl CoA to succinyl …
Virginiamycin S1
One of the components of virginiamycin, a cyclic polypeptide antibiotic complex from streptomyces virginiae, s. Loidensis, s. Mitakaensis, s. Pristina-spiralis, s. Ostreogriseus, and others. It is used to treat infections with gram-positive organisms and as a growth promoter in cattle, swine, and poultry.
Experimental
Matched Description: … One of the components of virginiamycin, a cyclic polypeptide antibiotic complex from streptomyces virginiae …
Cediranib
The novel indole-ether quinazoline Cediranib is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.
Investigational
Matched Description: … It is being developed clinically as a once-daily oral therapy for the treatment of cancer. ... quinazoline Cediranib is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of …
rhIGFBP-3
rhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models of human. It is developed by Insmed and is currently under phase I of the clinical trial.
Investigational
Matched Description: … It is developed by Insmed and is currently under phase I of the clinical trial. ... anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models of …
Vicriviroc
Vicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1. This pyrimidine based drug inhibits the interaction of HIV-1 with CCR5, preventing viral entry into cells. This drug was developed by Schering-Plough.
Investigational
Matched Description: … Vicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of ... This pyrimidine based drug inhibits the interaction of HIV-1 with CCR5, preventing viral entry into cells …
Roxarsone
Roxarsone is an organoarsenic molecule added to poultry feed. The addition of this compound to poultry feed improves weight gain and feed efficiency as well as prevent the growth of coccidian parasites. The drug is also approved in the United States for use in pigs.
Vet approved
Matched Description: … the growth of coccidian parasites. ... The addition of this compound to poultry feed improves weight gain and feed efficiency as well as prevent …
Matrix-M
Matrix-M is a saponin-based adjuvant made of nanometer particles, cholesterol, and phospholipid that is developed by Novavax. This compound is administered alongside vaccines to enhance biological functions: creating robust and long-lasting immune responses that may allow for dose-sparing of vaccines.
Investigational
Matched Description: … Matrix-M is a saponin-based adjuvant made of nanometer particles, cholesterol, and phospholipid that ... biological functions: creating robust and long-lasting immune responses that may allow for dose-sparing of …
Pegsitacianine
Pegsitacianine is under investigation in clinical trial NCT05576974 (A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)).
Investigational
Matched Description: … NCT05576974 (A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of ... Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients …
ATL1102
ATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, an immune cell molecule. It works by entering cells and targeting genes.
Investigational
Matched Description: … ATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, …
Laromustine
VNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia, Lymphoma, Lung Cancer, Small Intestine Cancer, and Myelodysplastic Syndromes, among others.
Investigational
Matched Description: … VNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia …
Tandamine
Tandamine was researched in 1970s as an antidepressant but was never commercialized. Tandamine is an analog of pirandamine and it acts as a selective serotonin reuptake inhibitor (SSRI).
Experimental
Matched Description: … Tandamine is an analog of pirandamine and it acts as a selective serotonin reuptake inhibitor (SSRI). …
Eleclazine
Eleclazine has been used in trials studying the treatment of LQT2 Syndrome, Long QT Syndrome, Ischemic Heart Disease, Ventricular Arrhythmia, and Long QT Syndrome Type 3, among others.
Investigational
Matched Description: … Eleclazine has been used in trials studying the treatment of LQT2 Syndrome, Long QT Syndrome, Ischemic …
MIP-1095 I-123
123 I Mip 1095 is under investigation in clinical trial NCT00712829 (Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents).
Investigational
Matched Description: … NCT00712829 (Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of …
Displaying drugs 6676 - 6700 of 8282 in total